Holding(s) in Company

London Stock Exchange

FRENKEL TOPPING GROUP PLC

Released 15:30:50 19 August 202019 August 2020

RNS Number : 6213W Frenkel Topping Group PLC

19 August 2020

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)¹

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:	Frenkel Topping Group	
1b. Please indicate if the issuer is a non-UK issue	r (please mark with an "X" if appropriate)	
Non-UK issuer		
2. Reason for the notification (please mark the app	propriate box or boxes with an "X")	
An acquisition or disposal of voting rights		
An acquisition or disposal of financial instruments		
An event changing the breakdown of voting rights		
Other (please specify)::		
3. Details of person subject to the notification ob	ligation [⊮]	
Name	Killik & Co LLP	
City and country of registered office (if applicable)	London, Uk	
4. Full name of shareholder(s) (if different from 3.)		
Name	Platform Securities (on behalf of various discretionary clients of Killik & Co LLP)	
City and country of registered office (if applicable)	London, UK	
5. Date on which the threshold was crossed or reached ¹ :	18/08/2020	
6. Date on which issuer notified (DD/MM/YYYY):	'): 19/08/2020	

7. Total positions	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}
Resulting situation on the date on which threshold was crossed or reached	4.28	N/A	4.28	108,051,641
Position of previous notification (if applicable)	2.26	N/A	2.26	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type of shares	Number of voting rights [∞]		% of voting rights	
ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00B01YXQ71	4,620,376		4.28 % shares held	
SUBTOTAL 8. A	4,620,376		4.28	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration date* Exercise/ Conversion Period* Exercised/converted. Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights exercised/converted.

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period xi	Physical or cash settlementxii	Number of voting rights	% of voting rights
	·	•	SUBTOTAL 8.B.2		

9. Information in relation applicable box with an "X	on to the person subject to X")	the notification obligat	ion (please mark the	
	cation obligation is not controlle taking(s) holding directly or inc			
	lertakings through which the vo ffectively held starting with the s as necessary)		erson or legal entity ^{xiv}	
Name∞	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it eq or is higher than t notifiable thresho	he
10. In case of proxy votin	g, please identify:			
Name of the proxy holder				
The number and % of voting rights held				
The date until which the voting rights will be held				

11. Additional information^{xvi}

Place of completion	Middle Office. Killik & Co LLP, Crown House, Crown Street, Ipswich, Suffolk, IP1 3HS
Date of completion	19/08/2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END